Does Orgenesis Inc. (ORGS) Have More Gas After Reaching 52-Week High?

March 15, 2018 - By Richard Conner

The stock of Orgenesis Inc. (NASDAQ:ORGS) hit a new 52-week high and has $15.79 target or 6.00 % above today’s $14.90 share price. The 9 months bullish chart indicates low risk for the $153.03 million company. The 1-year high was reported on Mar, 15 by If the $15.79 price target is reached, the company will be worth $9.18 million more.
The 52-week high event is an important milestone for every stock because it shows very positive momentum and is time when buyers come in. During such notable technical setup, fundamental investors usually stay away and are careful shorting or selling the stock.

The stock increased 7.24% or $1.0057 during the last trading session, reaching $14.8957. About 325,078 shares traded or 595.19% up from the average. Orgenesis Inc. (NASDAQ:ORGS) has 0.00% since March 15, 2017 and is . It has underperformed by 16.70% the S&P500.

Analysts await Orgenesis Inc. (NASDAQ:ORGS) to report earnings on May, 23.

More notable recent Orgenesis Inc. (NASDAQ:ORGS) news were published by: which released: “Orgenesis Completes Reverse Stock Split” on November 16, 2017, also with their article: “Orgenesis Acquires Cell Therapy Manufacturer MaSTherCell” published on March 09, 2015, published: “Orgenesis Inc.” on June 12, 2017. More interesting news about Orgenesis Inc. (NASDAQ:ORGS) were released by: and their article: “Orgenesis Announces a Strategic Corporate Regrouping of its CDMO Activities …” published on January 22, 2018 as well as‘s news article titled: “Orgenesis Reports 78% Increase in Revenue for the Fourth Quarter of Fiscal 2017” with publication date: March 05, 2018.

Orgenesis Inc., a biopharmaceutical company, develops trans-differentiation technologies in the field of cell therapy and regenerative medicine. The company has market cap of $153.03 million. The company's Contract Development and Manufacturing Organization segment specializes in cell therapy development for advanced medicinal products. It currently has negative earnings. This segment provides process and assay development services; and GMP contract manufacturing services.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.